TCGA-NC-A5HI-01A-11R-A26W-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.450
- G2M_CHECKPOINT+0.390
- OXIDATIVE_PHOSPHORYLATION+0.280
- MYC_TARGETS_V1+0.250
- DNA_REPAIR+0.190
- FATTY_ACID_METABOLISM+0.190
- MYC_TARGETS_V2+0.160
- MTORC1_SIGNALING+0.070
- PI3K_AKT_MTOR_SIGNALING+0.060
- SPERMATOGENESIS+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.670
- INTERFERON_GAMMA_RESPONSE-0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- INFLAMMATORY_RESPONSE-0.490
- TGF_BETA_SIGNALING-0.490
- ALLOGRAFT_REJECTION-0.460
- COMPLEMENT-0.450
- TNFA_SIGNALING_VIA_NFKB-0.440
- UV_RESPONSE_DN-0.440
- ANGIOGENESIS-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR3147738 | — | — | 0.922 |
| 2 | BS_NKEAAFMW | medulloblastoma | — | 0.915 |
| 3 | TCGA-GV-A40G-01A-11R-A23N-07 | — | — | 0.909 |
| 4 | TCGA-77-A5G7-01B-11R-A27Q-07 | — | cohortSQ1 | 0.907 |
| 5 | SRR8518240 | — | E | 0.907 |
| 6 | TCGA-CV-6948-01A-11R-1915-07 | — | — | 0.907 |
| 7 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.905 |
| 8 | TCGA-CR-6472-01A-11R-1873-07 | — | — | 0.904 |
| 9 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.901 |
| 10 | SAMN03290891 | — | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |